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Abstract: Trp(Nps)-Lys-NH2 derivatives, bearing alkyl or guanidine groups either at the 
N–terminus or on the Lys side-chain or at both positions were conveniently prepared on 
solid-phase and evaluated as TRPV1 channel antagonists.  
Keywords: solid-phase; Trp(Nps) dipeptides; TRPV1 channel blockers 
 
1. Introduction 
TRPV1 (Transient Receptor Potential Vanilloid 1) is a non-selective, Ca2+ preferring, ion channel, 
activated by temperatures higher than 42 ºC, acidic pH, vanilloids such as capsaicin, and the 
endogenous cannabinoid receptor ligand anandamide [1]. TRPV1 expression is up-regulated in a 
number of painful disorders, including chronic, neuropathic and acute inflammatory pain, and 
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consequently, it is a promising therapeutic target for pain relief [1,2]. In this respect, numerous 
research programs have been dedicated to the search of TRPV1 modulators to be used as 
pharmacological tools for better understanding the pharmacology of this cation channel. In addition, 
few modulators that emerged from these programs have reached clinical trials for multiple therapeutic 
indications [3,4]. However, due to possible side effect issues, such as diminished response to damaging 
heat stimuli, altered body temperature and reduction in the perception of taste, the development of 
TRPV1 antagonists as analgesic drugs still needs compounds with greater efficacy and fewer adverse 
effects [3,4]. 
Like ruthenium red [5], Arg-rich peptides have been described as non-competitive antagonists of 
TRPV1 receptors, through binding to a site located near the entryway of the aqueous pore [6]. A few 
years ago, we found that dipeptide derivatives Xaa-Trp(Nps) and Trp(Nps)-Xaa (Xaa=Lys, Arg,  
Nps = 2-o-nitrophenylsulfenyl), first described as analgesic dipeptides of unknown mechanism of 
action [7,8], inhibited the activation of TRPV1 in the micromolar range, and also acted as NMDA 
channel blockers, although with lower potency [9]. In view of their structural analogy with the Arg-
rich peptides, it was hypothesized that these Nps-containing dipeptides could interact with the 
vanilloid receptor through the pore entrance. Now, in an attempt to fine-tune the potency/selectivity 
balance within this family of channel blockers, we have prepared and evaluated a new series of H-
Trp(Nps)-Lys-NH2 dipeptide derivatives, incorporating alkyl and guanidino moieties at the N–terminal 
group and on the Lys side-chain. This paper deals with the solid-phase synthesis and the biological 
activity displayed by this new series of Trp(Nps)-containing dipeptides, compared to model 
compounds H-Trp(Nps)-Lys-NH2 (1) and H-Trp(Nps)-Arg-NH2 (2). 
2. Results and Discussion  
2.1. Synthesis 
The synthesis of the Trp(Nps)-Lys-NH2 dipeptide derivatives was performed by parallel solid-
phase synthesis on a Rink-amide MBHA polystyrene resin (NH2-PS), following a Fmoc/tBu strategy 
(Scheme 1). Fmoc-Trp-Lys(Boc)-NH-PS (3) and Fmoc-Trp-Lys(Alloc)-NH-PS (4) were prepared 
from the corresponding amino acid derivatives as appropriate intermediates for modifications at the N–
terminus and the Lys side-chain, respectively. Then the most demanding step, the incorporation of the 
Nps moiety, was performed by reaction with 2-nitrobenzenesulphenyl chloride (Nps-Cl) in an 8:2 
AcOH-DMF mixture, to produce dipeptidyl resins 5 and 6. After the orthogonal removal of the Fmoc 
group of 5, two portions of the resin were subjected to reductive amination by condensation with 
benzaldehyde and isobutylaldehyde, followed by treatment with NaBH3CN [10], to give compounds 7 
and 8. Additional aliquots of the Fmoc intermediate 5 were deprotected and then treated with N,N-
di(Boc)-S-methylisothiourea, HBTU and HBPyU in the presence of a base to provide the 
corresponding N-guanylated derivatives 9-11 [11,12]. Finally, resin-bound derivatives 7-11 were 
cleaved from the resin with TFA:H2O (19:1, v/v) to render the corresponding N-alkyl (17, 18) and N-
guanidyl derivatives 19-21 in low-moderate yield and high purity after extraction in reverse-phase 
cartridges. When the same reactions were applied to dipeptidyl resin 6, after Alloc removal, the 
expected Nε-benzyl and Nε-isobutyl derivatives 22a, 23a were obtained after cleavage. However, 
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guanidylation reactions mainly resulted in the corresponding diguanidylated compounds 24b-26b. A 
plausible explanation could be that the free amino group of the Lys side-chain, generated after removal 
of the Alloc group, could be basic enough under the guanidylation reaction conditions to promote the 
Fmoc removal in intermediate 6.  
Scheme 1. Synthesis of Trp(Nps)-containing dipeptide derivatives. 
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Reagents and Conditions: i) Nps-Cl, AcOH:DMF 8:2, Ar, 3 h, r.t.; ii) 20% pip/DMF; iii) 
PhCHO/TMOF, 6 h, r.t.; NaBH3CN/AcOH 1%/TMOF, 16h, r.t.; or iPrCHO/TMOF, 6 h, r.t.; 
NaBH3CN/AcOH 1%/TMOF, 16 h, r.t.; or MeSC(NHBoc)(=NBoc)/HgCl2/TEA/DCM, Ar, r.t., 16 
h; or HBTU/DIEA/DMF, 16 h, r.t.; or HBPyU/DIEA/DMF, 16 h, r.t.; iv) cleavage: TFA:H2O 19:1, 
r.t., 2 h; v) 2 x [Pd(PPh3)4/PhSiH3, DCM, Ar, 1 h, r.t.]. 
As reported by Farrera-Sinfreu et al. [13], this undesired removal of the Fmoc group from Lys 
peptides seems to be time- and base-dependent, and could be prevented by quick chemical capture of 
the ε–NH2 group, not applicable in our case. Accordingly, the treatment with N,N-di(Boc)-S-
methylisothiourea, requiring the presence of mercury (II) chloride as catalyst and TEA and repeated 
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twice for reaction completion [11], the only isolated product was the disubstituted compound 24b. 
However, guanidylation using HBTU or HBPyU in the presence of DIEA led to inseparable mixtures 
of mono- and di-substituted derivatives, 25a + 25b and 26a + 26b in a ~1:3 ratio (Scheme 1, Table 1). 
All compounds were obtained as single diastereoisomers, as deduced by HPLC and 1H-NMR, 
indicating the stereochemical integrity of all the steps in the process.  
Table 1. Final compounds and intermediates prepared. 
Compound R1 Compound R1 R2 
7, 17 
 
12, 22 – 
8, 18 
 
13, 23 – 
9, 19 
 
14b, 24b 
 
10, 20 
 
15a, 25a – 
11, 21 
 
15b, 25b 
  
  16a, 26a – 
  16b, 26b 
 
2.2. Biological activity 
Compounds 17-26 were evaluated for their ability to inhibit Ca2+ influx through TRPV1 channels, 
activated by capsaicin, and to block the glutamate-evoked activity of NMDA receptors (Figure 1). 
Model compounds 1 and 2 were included for comparative purposes. As shown in Figure 1, the 
incorporation of alkyl groups at the N–terminus of Trp residue decreases (iBu, 17) or maintains (Bzl, 
18) the TRPV1 blockage with respect to the parent compound H-Trp(Nps)-Lys-NH2 (1). A free 
guanidinium moiety at this position also reduces the TRPV1 antagonist properties, while the 
incorporation of tetramethyl- and pyrrolidyl-substituted guanidinos improves the percentage of TRPV1 
blockage (20 and 21). It is noteworthy that, in general, substitution at the N–terminus leads to better 
TRPV1/NMDA selectivity than the model dipeptide derivative.  
Nε-Alkyl Lys derivatives 22a and 23a show comparable and slightly better activity and enhanced 
selectivity with respect to the Lys-model dipeptide 1. Compared to the H-Trp(Nps)-Arg-NH2 (2) 
prototype, diguanidino derivatives 24b-25b do not result in significant improvement of the blocking 
effects. While they either retain or slightly improve TRPV1 blockade, selectivity towards NMDA 
diminished, especially for compound 24b, with two free guanidino groups. 
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Figure 1. Blockage of TRPV1 and NMDA activity by compounds 17-26. Each bar 
represents the mean ± SEM, n = 12. 
 
3. Experimental 
3.1. General  
All reagents were of commercial quality. Solvents were dried and purified by standard methods. 1H- 
NMR spectra were recorded at 300 MHz on a Varian XL-300 instrument (samples at 5−10 mM 
concentrations). Electrospray mass spectra (ES-MS) were performed, in positive ion mode, on a 
Hewlett-Packard 1100SD or an HPLC-MS WATERS equipment, the last integrated by a 2695 
separation module, a 2996 photodiode array detector and a Micromass ZQ 2000 spectrometer. 
Analytical HPLC chromatograms were done on a C18 reverse-phase column (SunFire C18, 4.6 × 50 
mm; Flow rate: 1 mL/min; Gradient: 10% A to 50% A in 8 min, were A: CH3CN + 0.08% formic acid 
and B: H2O + 0.1% formic acid). The solid-phase syntheses were carried out manually, on plastic 
syringes with a porous filter, and attached to a vacuum manifold for fast removal of excess of reagents 
and solvent. Resins were swollen in DCM/DMF/DCM/DMF (4 × 0.5 min).  
3.2. General procedure for the synthesis of Fmoc-Trp(Nps)-Lys(Boc or Alloc)-NH-PS (5, 6) 
Previously swollen Rink amide-MBHA resin (1.0 g, 0.46 mmol) was treated with 20% piperidine in 
DMF for 30 min to remove the Fmoc group. After washing with DMF and DCM, the corresponding 
amino acid, N-Fmoc-L-Lys(Boc)-OH (0.32 g, 0.69 mmol) or N-Fmoc-L-Lys(Alloc)-OH (0.31 g,  
0.69 mmol), HOBt (0.93 g, 0.7 mmol) and DIC (0.1 mL, 0.7 mmol) in anhydrous DMF (3 mL) were 
added. Couplings were allowed to proceed at room temperature overnight. The resins were washed 
repeatedly with DMF and DCM (5 × 0.5 min each). Then, the Fmoc group was removed by the above 
described treatment, and a second coupling with N-Fmoc-L-Trp-OH (0.29 g, 0.69 mmol), HOBt  
(0.93 g, 0.69 mmol) and DIC (0.1 mL, 0.69 mmol) in anhydrous DMF (3 mL) was performed. After 
coupling completion (as assessed by the nynhidrin test), the resins were washed with anhydrous DMF, 
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and a solution of Nps-Cl (0.23 mg, 1.118 mmol) in AcOH:DMF (8:2, 2 mL) was added under Ar. The 
mixture was allowed to stand for 3 h at r.t., and then repeatedly washed with DMF and DCM  
(5 × 0.5 min each). 
3.3. Typical procedure for Alloc removal 
To the pre-swollen resin, under Ar atmosphere, dried DCM (1 mL) and phenylsilane (25 equiv.) 
were added. After 5 min, a solution of Pd[PPh3]4 (0.1 equiv.) in dried DCM (1 mL) was added and the 
mixture was allowed to stand for 1 h 30 min. After this time the resin was drained off, washed with 
DCM (5 x 1 min) and the deprotection procedure was repeated once more, allowing the mixture to 
stand for 30 min. Finally, the resin was successively washed with DCM/dioxane-H2O 
(9:1)/DMF/DCM (5 × 1 min). 
3.4. Reductive amination 
After removal of the Fmoc (compound 5) or Alloc (compound 6) protecting groups, the resulting 
resins (0.11 mmol) were washed with DMF (5 × 0.5 min), and trimethyl orthoformate (TMOF)  
(2 × 0.5 min). Then, TMOF (0.5 mL) and the desired aldehyde (benzaldehyde or isobutyraldehyde, 
0.33 mmol) were added. Formation of the imine at r.t. for 6 h was followed by filtration to remove the 
excess of aldehyde, addition of TMOF (1 mL), and addition of NaBH3CN (0.33 mmol), in the presence 
of AcOH 1% (0.01 mL) for 16 h.  
3.5. Guanidylation reactions 
3.5.1. N,N-di(Boc)-S-methylisothiourea as reagent 
To the previously swollen resins 5 and 6 (0.11 mmol), and after removal of Fmoc or Alloc groups, 
respectively, a solution of N,N-di(Boc)-S-methylisothiourea (0.13 mmol) in anhydrous DCM (1 mL) 
was added under Ar. Then, HgCl2 (0.22 mmol) and TEA (0.33 mmol) were successively added under 
Ar, and the reaction allowed to stand at r.t. overnight. This process was repeated once and then, the 
resins were drained and washed [DCM/DMF/DMF:MeOH (1:1.5)/DMF/DCM (5 × 0.5 min each)]. 
3.5.2. HBTU or HBPyU as reagent 
After removing the Fmoc and Alloc group from resins 5 and 6 (0.11 mmol), a solution of HBTU 
(0.275 mmol) or HBPyU (0.33 mmol) and DIEA (0.275 or 0.33 mmol, respectively) in anhydrous 
DMF (1 mL) was added, and the reaction allowed to stand at r.t. overnight. The resins were drained 
and washed [DMF /DCM/DMF/DCM (5 × 0.5 min each)]. 
3.5.3. Cleavage reactions  
For resins 12-16, the removal of the Fmoc protecting group before cleavage was required. Resins  
7-11 and 12-16 were treated with a mixture of TFA-H2O, 19:1 (1 mL for 100 mg) at r.t. for 2 h. After 
washings with DCM (5 × 1mL), the filtrates were evaporated and the residue solved in water and 
washed with ethyl acetate. The aqueous phase was lyophilized to give derivatives 17-26, isolated as 
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trifluoroacetate salts. When required, the products were purified through reverse-phase cartridges using 
mixtures of H2O/ACN as solvent.  
iBu-Trp(Nps)-Lys-NH2 (17): Yield: 4%. HPLC: tR = 2.76 min. 1H-NMR (D2O):, δ 0.77 (d, 6H, 2CΗ3 
iBu, J = 6.6), 0.98 (m, 2H, γ−Η Lys), 1.3-1.4 (m, 4H, β and δ−H Lys), 1.81 (sept, 1H, CH iBu,  
J = 6.7 Hz), 2.5-2.8 (m, 4H, ε−Η Lys and CH2 iBu), 3.2-3.3 (m, 2H, β−H Trp), 3.87-3.94 (m, 2H, α−H 
Lys and α−H Trp), 6.47 (d, 1H, Η6 Nps, J = 7.8 Hz), 7.01 (t, 1H, H5 Indole, J = 7.2 Hz), 7.1-7.2 (m, 
3H, H6 Indole, H4 and H5 Nps), 7.29 (d, 1H, H7 Indol, J = 8.1 Hz), 7.42 (d, 1H, H4 Indole, J = 8.8 Hz), 
8.1 (d, 1H, H3 Nps, J = 7.8 Hz).  Calc. MW = 540.68, MS ESI+ [M+H]+ m/z: 541. 
Bn-Trp(Nps)-Lys-NH2 (18): Yield: 24%. HPLC: tR = 3.42 min. 1H-NMR (D2O):, δ 1.03 (m, 2H, γ−Η 
Lys), 1.3-1.5 (m, 4H, β and δ−H Lys), 2.69 (t, 2H, ε−Η Lys, J = 7.6 Hz), 3.20 (m, 2H, β−H Trp), 3.94 
(t, 1H, α−H Lys, J = 7.0 Hz), 4.02 (t, 1H, α−H Trp, J = 6.0 Hz), 4.60 (m, 2H, CH2 Bn), 6.44 (dd, 1H, 
Η6 Nps, J=7.8 and 1.2 Hz), 7.02 (t, 1H, H5 Indole, J = 7.0 Hz), 7.1-7.3 (m, 9H, H6 and H7 Indole, H4 
and H5 Nps, and 5H Ph), 7.44 (dd, 1H, H4 Indole, J = 7.9 and 0.75 Hz), 8.1 (dt, 1H, H3 Nps,  
J = 7.8 and 1.5 Hz). Calc. MW = 574.69, MS ESI+ [M+H]+ m/z: 575.  
[H2N-C(=NH)]-Trp(Nps)-Lys-NH2 (19): Yield: 36%. HPLC: tR = 2.41 min. 1H-NMR (D2O): δ 1.07 (m, 
2H, γ−Η Lys), 1.3-1.5 (m, 4H, β and δ−H Lys), 2.70 (t, 2H, ε−Η Lys, J = 7.5 Hz), 3.2-3.3 (m, 2H, β−H 
Trp), 3.99 (t, 1H, α−H Lys, J = 7.05 Hz), 4.34 (t, 1H, α−H Trp, J = 5.8 Hz), 6.45 (d, 1H, Η6 Nps,  
J =7.8 Hz), 7.01 (t, 1H, H5 Indole, J = 7.5 Hz), 7.1-7.2 (m, 3H, H6 Indole, H4 and H5 Nps), 7.28 (d, 1H, 
H7 Indole, J = 8.4 Hz), 7.43 (d, 1H, H4 Indole, J = 8.1 Hz), 8.1 (d, 1H, H3 Nps, J = 7.8 Hz). Calc.  
MW = 526.61, MS ESI+ [M+H]+ m/z: 527.  
[[(CH3)2N]2-C=]-Trp(Nps)-Lys-NH2 (20): Yield: 35%. 1H-NMR (D2O): δ 1.11 (m, 2H, γ−Η Lys),  
1.4-1.5 (m, 4H, β and δ−H Lys), 2.69-2.77 (m, 14H, 2 ε−Η Lys and 4CH3-N), 3.22 (m, 2H, β−H Trp), 
3.95 (t, 1H, α−H Lys, J = 6.9 Hz), 4.24 (t, 1H, α−H Trp, J = 7.8 Hz), 6.54 (d, 1H, Η6  Nps,  
J = 7.8 Hz), 7.07 (t, 1H, H5 Indole, J = 7.3 Hz), 7.1-7.3 (m, 3H, H6 Indole, H4 and H5 Nps), 7.35 (d, 
1H, H7 Indol, J = 8.4 Hz), 7.52 (d, 1H, H4 Indole, J = 8.1 Hz), 8.1 (dd, 1H, H3 Nps, J = 8.2 and  
1.5 Hz). Calc. MW = 582.72, MS ESI+ [M+H]+ m/z: 583.  
[[(C4H8)2N]2-C=]-Trp(Nps)-Lys-NH2 (21): Yield: 47%. HPLC: tR = 3.79 min. 1H-NMR (D2O): δ 1.05 
(m, 2H, γ−Η Lys), 1.3-1.5 (m, 4H, β and δ−H Lys), 1.62 (s, 8H, CCH2C Pyrrolidino), 2.71 (t, 2H, ε−Η 
Lys, J = 7.5 Hz), 3.0-3.2 (m, 10H, 2 β−H Trp and 4CCH2N Pyrrolidino), 3.93 (t, 1H, α−H Lys,  
J = 6.9 Hz), 4.25 (t, 1H, α−H Trp, J = 6.7 Hz), 6.49 (d, 1H, Η6  Nps, J = 7.5 Hz), 7.0 (t, 1H, H5 Indole, 
J = 7.6 Hz), 7.1-7.2 (m, 3H, H6 Indole, H4 and H5 Nps), 7.29 (d, 1H, H7 Indole, J = 7.8 Hz), 7.44 (d, 
1H, H4 Indol, J = 7.8 Hz), 8.1 (d, 1H, H3 Nps, J = 8.1 Hz). Calc. MW = 634.79, MS ESI+ [M+H]+ m/z: 
635.  
H-Trp(Nps)-Lys(iBu)-NH2 (22a): Yield: 8%. 1H-NMR (D2O): δ 0.74 (d, 3H, 1CΗ3 iBu, J = 6.9 Hz), 
0.77 (d, 3H, 1CΗ3 iBu, J = 7.2 Hz), 1.06 (t, 1H, γ−Η Lys, J = 7.3 Hz), 1.3-1.4 (m, 4H, β and δ−H Lys), 
1.85 (m, 1H, CH iBu), 2.6-2.9 (m, 4H, ε−Η Lys and CH2 iBu), 3.18-3.21 (m, 2H, β−H Trp), 3.94 (t, 1H, 
α−H Lys, J = 7.2 Hz), 4.01 (t, 1H, α−H Trp, J = 7.5 Hz), 6.45 (d, 1H, Η6  Nps, J = 6.9 Hz), 7.03 (t, 1H, 
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H5 Indole, J = 7.5 Hz), 7.1-7.2 (m, 3H, H6 Indole, H4 and H5 Nps), 7.31 (d, 1H, H7 Indole, J = 8.1 Hz), 
7.45 (d, 1H, H4 Indole, J = 8.1 Hz), 8.1 (d, 1H, H3 Nps, J = 8.1 Hz). Calc. MW = 540.68, MS ESI+ 
[M+H]+ m/z: 541. 
H-Trp(Nps)-Lys(Bn)-NH2 (23a): Yield: 14%. 1H-NMR (D2O): δ 1.04 (m, 2H, γ−Η Lys), 1.3-1.4 (m, 
4H, β and δ−H Lys), 2.70 (t, 2H, ε−Η Lys, J = 7.6 Hz), 3.17 (m, 2H, β−H Trp), 3.9-4.0 (m, 2H, α−H 
Lys and α−H Trp), 4.60 (m, 2H, CH2 Bn), 6.45 (d, 1H, Η6  Nps, J=7.8), 7.03 (t, 1H, H5 Indole,  
J = 7.0 Hz), 7.1-7.3 (m, 9H, H6 and H7 Indole, H4 and H5 Nps, and 5H Ph), 7.45 (d, 1H, H4 Indole, 
 J = 8.1 Hz), 8.1 (dd, 1H, H3 Nps, J = 7.8 and 1.8 Hz). Calc. MW = 574.69, MS ESI+ [M+H]+ m/z: 575.  
[H2N-C(=NH)]-Trp(Nps)-Lys[C(=NH)-NH2]-NH2 (24b): Yield: 15%. 1H-NMR (D2O): δ 1.08 (m, 2H, 
γ−Η Lys), 1.3-1.6 (m, 4H, β and δ−H Lys), 2.94 (t, 2H, ε−Η Lys, J = 6.9 Hz), 3.24 (t, 2H, β−H Trp,  
J = 6.9 Hz), 4.04 (t, 1H, α−H Lys, J = 6.9 Hz), 4.40 (t, 1H, α−H Trp, J = 6.1 Hz), 6.52 (d, 1H, Η6  
Nps, J=7.8 Hz), 7.07 (t, 1H, H5 Indole, J = 7.5 Hz), 7.1-7.3 (m, 3H, H6 Indole, H4 and H5 Nps), 7.35 
(d, 1H, H7 Indol, J = 8.1 Hz), 7.51 (d, 1H, H4 Indole, J = 7.8 Hz), 8.2 (d, 1H, H3 Nps, J = 8.1 Hz). 
Calc. MW = 568.65, MS ESI+ [M+H]+ m/z: 569.  
[[(CH3)2N]2-C=]-Trp(Nps)-Lys[=C-[N(CH3)2]2]-NH2 (25b). Yield: 10% (as a 3:1 mixture with 
compound 25a). HPLC: tR = 4.68 min 25b and 3.33 min 25a. 1H-NMR 25b (D2O): δ 1.11 (m, 2H, γ−Η 
Lys), 1.1-1.4 (m, 4H, β and δ−H Lys), 2.74 (s, 12H, 4CH3-N), 2.95 (t, 2H, ε−Η Lys, J = 7.0 Hz),  
3.2-3.3 (m, 2H, β−H Trp), 3.94 (t, 1H, α−H Lys, J = 7.2 Hz), 4.24 (t, 1H, α−H Trp, J = 7.2 Hz), 6.54 
(d, 1H, Η6  Nps, J=7.8 Hz), 7.07 (t, 1H, H5 Indole, J = 7.8 Hz), 7.1-7.3 (m, 3H, H6 Indole, H4 and H5 
Nps), 7.35 (d, 1H, H7 Indole, J = 8.1 Hz), 7.52 (d, 1H, H4 Indole, J = 8.1 Hz), 8.1 (d, 1H, H3 Nps,  
J = 8.1 Hz). Calc. MW = 680.86 25b and MW = 582.72 25a, MS ESI+ [M+H]+ m/z: 681 (62%), 583 
(20%).  
[[(C4H8)2N]2-C=]-Trp(Nps)-Lys[=C-[(C4H8)2N]2]-NH2 (26b). Yield: 15% (as a 3:1 mixture with 
compound 26a). 1H-NMR 26b (D2O): δ 1.07 (m, 2H, γ−Η Lys), 1.3-1.6 (m, 4H, β and δ−H Lys), 1.68 
(s, 8H, CCH2C Pyrrolidino), 2.9-3.1 (m, 4H, ε−Η Lys and β−H Trp), 3.2 (s, 8H, 4CCH2N Pyrrolidino), 
3.95 (t, 1H, α−H Lys, J = 7.05 Hz), 4.28 (t, 1H, α−H Trp, J = 7.8 Hz), 6.51 (dd, 1H, Η6 Nps,  
J = 8.1 and 1,2 Hz), 7.02 (t, 1H, H5 Indole, J = 7.5 Hz), 7.1-7.2 (m, 3H, H6 Indole, H4 and H5 Nps), 
7.30 (d, 1H, H7 Indole, J = 7.8 Hz), 7.47 (d, 1H, H4 Indole, J = 7.8 Hz), 8.1 (dd, 1H, H3 Nps,  
J = 7.9 and 1.3 Hz). Calc. MW = 785.01, 26b and MW = 634.79, 26a, MS ESI+ [M+H]+ m/z: 786 
(36%), 635 (12%). . 
3.6. Biological activity 
Recombinant rat TRPV1 and human NMDAR channel expression in Xenopus oocytes and channel 
blockade: All the procedures have been described in detail elsewhere [6,14]. Briefly, capped cRNA for 
TRPV1 (kindly provided by Dr. David Julius, University of California, San Francisco), and the NR1 
and NR2A subunits of the NMDA receptor was synthesized from linearized cDNA by using the 
mMESSAGE mMACHINE from AMBION (Texas). cRNA (0.2 mg mL-1) was microinjected  
(V = 50 nL) into defolliculated oocytes (Stage V and VI) as described. Oocytes were functionally 
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assayed 2–4 days after cRNA injection. Whole-cell currents from rat TRPV1-injected oocytes were 
recorded in standard Ringer solution (10 mM HEPES, pH 7.4, 115 mM NaCl, 2.8 mM KCl, 2.8 mM 
BaCl2) with a two-microelectrode voltage-clamp amplifier at 20 ºC. TRPV1 channels were activated 
by application of 10 µM capsaicin in the absence or presence of compounds (10 µM) at a holding 
potential (Vh) of −60 mV. Whole-cell currents from oocytes injected with NR1/NR2A (1:3, w/w) 
subunits were recorded in standard Ringer solution upon activation with L-glutamate (100 µM) 
supplemented with glycine (10 µM) at Vh = −60 mV. Responses were normalized with respect to that 
evoked without channel blockers. Experiments were performed in triplicate; each bar in Figure 1 
represents the mean ± SEM, n (number of oocytes) = 12. 
4. Conclusions 
Convenient solid-phase procedures have been developed for the modification of Trp(Nps)-Lys 
dipeptides at the N-terminus or on the Lys side-chain. Main steps of these procedures are the AcOH-
catalyzed incorporation of the Nps moiety at the indole ring, compatible with TFA labile resins, the 
reductive amination to N-alkyl derivatives, and the guanidylation reactions with thioureas or uronium 
salts. Diguanidylated by-products were obtained during the incorporation of guanidino groups on the 
Lys side-chain, probably due to Fmoc-removal by the free Lys ε–NH2 group under the basic media. 
From the biological point of view, the presence of substituted guanidino groups at N-terminus led to 
the best TRPV1 activity/NMDA selectivity ratio. Based on the significant activation of NMDA 
receptor by compound 20 (∼30%), derivative 21 could be considered as a suitable molecule for further 
modifications in the search for new TRPV1 channel blockers. 
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